로딩 중…
StockDiggingStockDigging

Bio Plus Co., Ltd

099430· KOSDAQ
₩4,345-2.03%
2026-06-19

Price Chart

Bio Plus Co., Ltd-40.56%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap267.83B KRW
Revenue94.42B KRW
Net Income2.31B KRW
Total Assets297.50B KRW
Net Assets199.02B KRW
Employees155
Value
P/E116.04x
P/B1.35x
PEG29.32x
P/S2.84x
FCF Yield-11.89%
Profitability
ROE1.16%
ROA0.78%
Op. Margin-0.52%
Revenue Growth15.35%
Earnings Growth3.96%
Financial Health
Debt Ratio149.48%
Total Debt79.60B KRW
FCF-31.84B KRW
Cash23.02B KRW
Current Ratio0.94x
Dividend
Div. Yield1.58%
Div. Growth40.00%
Performance
1Y Return-40.56%
1M Return-15.14%
From 52W High-47.96%
1Y MDD-45.60%
Trading
Volume538,242 shares
Foreign Own.3.04%
Per Share
EPS228 KRW
BPS2,885 KRW

Company Info

CEO 정현규
Employees 155
Founded 2003
HQ 경기도 성남시, KR

Established in 2003 and rebranded in 2013, the company expanded its business in 2025 by establishing BioPlus USA Inc. and acquiring equity. It primarily focuses on the research, development, manufacturing, and sales of hyaluronic acid-based medical devices and Bio Cosmetic products, while also concentrating on developing next-generation botulinum toxin and obesity treatments. Employing a technology-driven strategy, the company exports to over 70 overseas countries and is accelerating its global market entry by establishing an overseas subsidiary and local production facilities in China. BioPlus was established in 2003 and is headquartered in Gyeonggi-do, Seongnam-si.